Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NPCE Stock Forecast 2026-2027
$16.91
Current Price
$563.23M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NPCE Price Targets
+30.1%
To High Target of $22.00
+15.3%
To Median Target of $19.50
-11.3%
To Low Target of $15.00
NPCE Price Momentum
+3.2%
1 Week Change
+4.4%
1 Month Change
+39.6%
1 Year Change
+9.5%
Year-to-Date Change
-10.9%
From 52W High of $18.98
+123.6%
From 52W Low of $7.56
📊 TOP ANALYST CALLS
Did NPCE Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if NeuroPace is one of their latest high-conviction picks.
Latest NPCE Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, NPCE has a bullish consensus with a median price target of $19.50 (ranging from $15.00 to $22.00). The overall analyst rating is N/A (N/A/10). Currently trading at $16.91, the median forecast implies a 15.3% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Priya Sachdeva at UBS, projecting a 30.1% upside. Conversely, the most conservative target is provided by Vik Chopra at Wells Fargo, suggesting a 11.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NPCE Analyst Ratings
8
Buy
0
Hold
0
Sell
NPCE Price Target Range
Low
$15.00
Average
$19.50
High
$22.00
Current: $16.91
Latest NPCE Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NPCE.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2025 | UBS | Priya Sachdeva | Buy | Maintains | $22.00 |
| Dec 10, 2025 | JP Morgan | Rohin Patel | Overweight | Maintains | $20.00 |
| Nov 5, 2025 | Wells Fargo | Vik Chopra | Overweight | Maintains | $16.00 |
| Nov 5, 2025 | JP Morgan | Rohin Patel | Overweight | Maintains | $18.00 |
| Aug 13, 2025 | Wells Fargo | Vik Chopra | Overweight | Maintains | $15.00 |
| May 28, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $18.00 |
| May 14, 2025 | JP Morgan | Robbie Marcus | Overweight | Maintains | $16.00 |
| May 14, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $17.00 |
| Apr 14, 2025 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Mar 5, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $20.00 |
| Jan 30, 2025 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $17.00 |
| Jan 21, 2025 | UBS | Priya Sachdeva | Buy | Initiates | $17.00 |
| Dec 17, 2024 | JP Morgan | Overweight | Maintains | $N/A | |
| Nov 13, 2024 | Wells Fargo | Vik Chopra | Overweight | Maintains | $13.00 |
| Aug 14, 2024 | Wells Fargo | Vik Chopra | Overweight | Maintains | $15.00 |
| Aug 14, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $18.00 |
| Jul 15, 2024 | Morgan Stanley | Drew Ranieri | Equal-Weight | Maintains | $8.00 |
| May 9, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $18.00 |
| Mar 14, 2024 | Wells Fargo | Lawrence Biegelsen | Overweight | Upgrade | $20.00 |
| Mar 12, 2024 | JP Morgan | Robbie Marcus | Overweight | Maintains | $17.00 |
NeuroPace Inc. (NPCE) Competitors
The following stocks are similar to NeuroPace based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
NeuroPace Inc. (NPCE) Financial Data
NeuroPace Inc. has a market capitalization of $563.23M with a P/E ratio of -18.2x. The company generates $94.86M in trailing twelve-month revenue with a -25.3% profit margin.
Revenue growth is +29.9% quarter-over-quarter, while maintaining an operating margin of -9.5% and return on equity of -169.3%.
Valuation Metrics
Market Cap
$563.23M
Enterprise Value
$568.41M
P/E Ratio
-18.2x
PEG Ratio
0.4x
Price/Sales
5.9x
Growth & Margins
Revenue Growth (YoY)
+29.9%
Gross Margin
+77.4%
Operating Margin
-9.5%
Net Margin
-25.3%
EPS Growth
+29.9%
Financial Health
Cash/Price Ratio
+10.7%
Current Ratio
4.9x
Debt/Equity
384.4x
ROE
-169.3%
ROA
-11.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
NeuroPace Inc. (NPCE) Business Model
About NeuroPace Inc.
What They Do
Develops neurostimulation solutions for neurological disorders.
Business Model
NeuroPace Inc. generates revenue primarily through the sale of its RNS System, an implantable device that mitigates epileptic seizures. The company targets patients with refractory epilepsy, offering them an alternative to traditional medication, thus creating a niche market in the neurology and medical devices sectors.
Additional Information
NeuroPace emphasizes advancements in patient-tailored therapy and precision medicine, showcasing its commitment to transforming epilepsy treatment. The company is poised for growth as it addresses the needs of patients who do not respond to conventional treatments, positioning itself as an influential player in the medical technology industry.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
209
CEO
Mr. Joel D. Becker
Country
United States
IPO Year
N/A
Website
www.neuropace.comNeuroPace Inc. (NPCE) Latest News & Analysis
Latest News
Quick Summary
NeuroPace, Inc. will present at the J.P. Morgan Healthcare Conference on January 14, 2026, and will hold investor meetings. The presentation will be available via live webcast.
Why It Matters
NeuroPace's participation in a major healthcare conference signals potential growth and innovation in epilepsy treatment, which could influence investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeuroPace, Inc. has filed a PMA-S application with the FDA to expand its RNS® System's indication for patients with ASM-resistant idiopathic generalized epilepsy and generalized tonic-clonic seizures.
Why It Matters
NeuroPace's FDA filing to expand its RNS® System for new epilepsy indications could significantly increase its market potential, influencing stock value and investor interest.
Source: Business Wire
Market Sentiment:
Neutral
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
1 month ago
Quick Summary
NeuroPace, Inc. presented preliminary 18-month results from its NAUTILUS1 trial at the AES meeting, assessing the RNS® System for treating medication-resistant idiopathic generalized epilepsy.
Why It Matters
Positive trial results for NeuroPace's RNS® System could boost its market position and stock value, indicating potential growth and increased investor interest in the epilepsy treatment sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeuroPace, Inc. will showcase its RNS System and NeuroPace AI platform at the 2025 American Epilepsy Society Annual Meeting, highlighting new clinical and AI advancements for epilepsy treatment.
Why It Matters
NeuroPace's showcase of advancements in epilepsy treatment and AI at a major conference can enhance its market position and attract investor interest, signaling potential growth and innovation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeuroPace, Inc. (Nasdaq: NPCE) announced positive Medicare reimbursement updates for its RNS® System, with increased payments for neurosurgeons under CY 2026 OPPS and Medicare PFS final rules.
Why It Matters
Favorable Medicare reimbursement updates for NeuroPace’s RNS System enhance revenue potential, improve profit margins, and may drive stock performance, positively influencing investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
NeuroPace, Inc. (NPCE) will hold its Q3 2025 earnings call on November 4, 2025, at 4:30 PM EST, featuring key executives and analysts from various financial institutions.
Why It Matters
NeuroPace's Q3 earnings call reveals financial performance and strategic direction, impacting stock valuation and investor sentiment. Analyst participation indicates interest and potential market implications.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About NPCE Stock
What is NeuroPace Inc.'s (NPCE) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, NeuroPace Inc. (NPCE) has a median price target of $19.50. The highest price target is $22.00 and the lowest is $15.00.
Is NPCE stock a good investment in 2026?
According to current analyst ratings, NPCE has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.91. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NPCE stock?
Wall Street analysts predict NPCE stock could reach $19.50 in the next 12 months. This represents a 15.3% increase from the current price of $16.91. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is NeuroPace Inc.'s business model?
NeuroPace Inc. generates revenue primarily through the sale of its RNS System, an implantable device that mitigates epileptic seizures. The company targets patients with refractory epilepsy, offering them an alternative to traditional medication, thus creating a niche market in the neurology and medical devices sectors.
What is the highest forecasted price for NPCE NeuroPace Inc.?
The highest price target for NPCE is $22.00 from Priya Sachdeva at UBS, which represents a 30.1% increase from the current price of $16.91.
What is the lowest forecasted price for NPCE NeuroPace Inc.?
The lowest price target for NPCE is $15.00 from Vik Chopra at Wells Fargo, which represents a -11.3% decrease from the current price of $16.91.
What is the overall NPCE consensus from analysts for NeuroPace Inc.?
The overall analyst consensus for NPCE is bullish. Out of 13 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $19.50.
How accurate are NPCE stock price projections?
Stock price projections, including those for NeuroPace Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 11:40 AM UTC